Environmental

Low Direct Environmental Footprint: 89bio (ETNB) operates as a clinical-stage biopharmaceutical company with no manufacturing facilities, resulting in a limited direct environmental impact compared to peers with commercial production operations.

Sustainable Supply Chain Practices: The company outsources manufacturing to third parties that are required to comply with environmental regulations, reducing direct emissions and hazardous waste risks.

Limited Climate Risk Exposure: ETNB’s business model and asset-light operations minimize exposure to climate transition and physical risks, as the company does not own or operate energy-intensive infrastructure.

ETNB’s environmental risk profile is favorable due to its clinical-stage, asset-light model and reliance on third-party manufacturing. The company’s limited operational footprint and regulatory compliance requirements for suppliers position it well relative to sector peers.

Social

Workforce Diversity and Inclusion: ETNB discloses basic diversity metrics and has policies supporting equal opportunity, but lacks comprehensive public targets or advanced programs compared to leading peers.

Clinical Trial Ethics and Patient Safety: The company adheres to Good Clinical Practice (GCP) standards and regulatory requirements for patient safety in clinical trials, a critical social risk for biopharma firms.

Community Engagement and Access: As a pre-commercial company, ETNB’s direct community impact is limited, but it has outlined commitments to future patient access and affordability in its pipeline disclosures.

ETNB demonstrates baseline social responsibility through compliance with clinical and workforce standards. However, the absence of advanced diversity initiatives and limited current community engagement constrain its social performance relative to best-in-class peers.

Governance

Experienced Leadership and Board: ETNB’s board and executive team have significant industry experience, supporting effective oversight and strategic direction.

Shareholder Rights and Board Independence: The board is majority independent and includes committees for audit, compensation, and governance, but the company maintains a classified board structure, which can limit shareholder influence.

Capital Discipline and Compensation: Stock-based compensation is high relative to revenue, reflecting the company’s early-stage status but raising dilution concerns for shareholders.

ETNB’s governance structure is sound in terms of board expertise and independence, but shareholder rights are somewhat constrained by staggered board terms and high equity-based pay. These factors are typical for clinical-stage biotech firms but represent moderate governance risks.

Overall Score

ETNB’s ESG profile is moderate overall. The company benefits from a low environmental risk profile and sound governance fundamentals, but social and governance scores are limited by the absence of advanced diversity initiatives, high stock-based compensation, and a classified board. These factors are consistent with sector norms for clinical-stage biotechs but leave room for improvement as the company matures.